![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
CR Ashby , LH Jiang, RJ Kasser and RY Wang
Department of Psychiatry and Behavioral Science, State University of New York, Stony Brook.
The aim of the present study was to characterize 5-hydroxytryptamine2 (5-HT2) receptors in the rat medial prefrontal cortex (mPFc) by single cell recording and microiontophoretic techniques. This was accomplished using 5-HT2 receptor agonists 1-[2,5-dimethoxy-4-iodophenyl]-2- aminopropane [(+/-)-DOI] and 1-[2,5-dimethoxy-4-bromophenyl]-2- aminopropane [(+/-)-DOB]. DOI ejected at a low current (0.5 nA) potentiates glutamate (GLU)-induced activation of mPFc neurons and this effect is blocked by spiperone. At higher currents. DOI invariably inhibits GLU-induced neuronal activity. The microiontophoretic ejection of both DOI and DOB predominantly inhibits spontaneously active mPFc cells. The inhibitory action of DOI on spontaneously active cells is dose-dependent and is blocked by putative 5-HT2 receptor antagonists, with a rank order of potency as follows: ritanserin greater than metergoline approximately LY-53857 greater than spiperone greater than mesulergine greater than mianserin approximately ketanserin. Interestingly, ketanserin and mianserin only weakly block the effect of DOI. The suppressant action of DOI is probably not related to its interaction with 5-HT10 sites as spiperone, which has low affinity for these sites, potently blocks the effect of DOI. The suppressant effect of DOI is not blocked by other receptor antagonists such as BRL-43694 (5-HT3), (+/-)-pindolol (5HT 1a,1b, beta adrenergic, beta), prazosin (adrenergic1, alpha-1), pyrilamine (histamine1, H1), l-sulpiride (dopamine2, D2) or SR 95103 (gamma-aminobutyric acid, GABAA). Overall our results indicate that DOI predominantly inhibits mPFc cells in a direct manner and this effect is mediated by 5-HT2 receptors.(ABSTRACT TRUNCATED AT 250 WORDS)
This article has been cited by other articles:
|
|
 |
|
  M. V. Puig, F. Artigas, and P. Celada Modulation of the Activity of Pyramidal Neurons in Rat Prefrontal Cortex by Raphe Stimulation In Vivo: Involvement of Serotonin and GABA Cereb Cortex, January 1, 2005; 15(1): 1 - 14. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. V. Puig, N. Santana, P. Celada, G. Mengod, and F. Artigas In Vivo Excitation of GABA Interneurons in the Medial Prefrontal Cortex through 5-HT3 Receptors Cereb Cortex, December 1, 2004; 14(12): 1365 - 1375. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Santana, A. Bortolozzi, J. Serrats, G. Mengod, and F. Artigas Expression of Serotonin1A and Serotonin2A Receptors in Pyramidal and GABAergic Neurons of the Rat Prefrontal Cortex Cereb Cortex, October 1, 2004; 14(10): 1100 - 1109. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Hirose, Y. Uwahodo, S. Yamada, T. Miwa, T. Kikuchi, H. Kitagawa, K. D. Burris, C. A. Altar, and T. Nabeshima Mechanism of Action of Aripiprazole Predicts Clinical Efficacy and a Favourable Side-Effect Profile J Psychopharmacol, September 1, 2004; 18(3): 375 - 383. [Abstract] [PDF]
|
|
|
|
|
|
M. Amargos-Bosch, A. Bortolozzi, M. V. Puig, J. Serrats, A. Adell, P. Celada, M. Toth, G. Mengod, and F. Artigas Co-expression and In Vivo Interaction of Serotonin1A and Serotonin2A Receptors in Pyramidal Neurons of Prefrontal Cortex Cereb Cortex, March 1, 2004; 14(3): 281 - 299. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. V. Puig, P. Celada, L. Diaz-Mataix, and F. Artigas In Vivo Modulation of the Activity of Pyramidal Neurons in the Rat Medial Prefrontal Cortex by 5-HT2A Receptors: Relationship to Thalamocortical Afferents Cereb Cortex, August 1, 2003; 13(8): 870 - 882. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. T. Szabo and P. Blier Effects of Serotonin (5-Hydroxytryptamine, 5-HT) Reuptake Inhibition Plus 5-HT2A Receptor Antagonism on the Firing Activity of Norepinephrine Neurons J. Pharmacol. Exp. Ther., September 1, 2002; 302(3): 983 - 991. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
